Yantai Dongcheng Pharmaceutical GroupLtd Toekomstige groei
Future criteriumcontroles 3/6
Yantai Dongcheng Pharmaceutical GroupLtd is forecast to grow earnings and revenue by 45.9% and 13.1% per annum respectively. EPS is expected to grow by 45.8% per annum. Return on equity is forecast to be 7.6% in 3 years.
Belangrijke informatie
45.9%
Groei van de winst
45.8%
Groei van de winst per aandeel
Biotechs winstgroei | 44.8% |
Inkomstengroei | 13.1% |
Toekomstig rendement op eigen vermogen | 7.6% |
Dekking van analisten | Good |
Laatst bijgewerkt | 01 Nov 2024 |
Recente toekomstige groei-updates
Recent updates
Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) Has A Pretty Healthy Balance Sheet
Aug 23Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) Business Is Yet to Catch Up With Its Share Price
Jul 12News Flash: 7 Analysts Think Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (SZSE:002675) Earnings Are Under Threat
May 06Yantai Dongcheng Pharmaceutical GroupLtd's (SZSE:002675) Problems Go Beyond Weak Profit
May 05Is Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) A Risky Investment?
Mar 15Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) P/E Is On The Mark
Feb 27Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 3,906 | 424 | N/A | 760 | 5 |
12/31/2025 | 3,452 | 327 | N/A | 664 | 6 |
12/31/2024 | 3,119 | 258 | N/A | 648 | 6 |
9/30/2024 | 2,853 | 91 | -167 | 362 | N/A |
6/30/2024 | 2,911 | 137 | -280 | 247 | N/A |
3/31/2024 | 3,072 | 224 | -340 | 204 | N/A |
12/31/2023 | 3,276 | 210 | -235 | 277 | N/A |
9/30/2023 | 3,427 | 263 | 35 | 490 | N/A |
6/30/2023 | 3,603 | 323 | 199 | 664 | N/A |
3/31/2023 | 3,554 | 302 | 467 | 853 | N/A |
1/1/2023 | 3,583 | 307 | 607 | 997 | N/A |
9/30/2022 | 3,858 | 220 | 415 | 986 | N/A |
6/30/2022 | 3,851 | 165 | 292 | 833 | N/A |
3/31/2022 | 3,902 | 140 | 295 | 846 | N/A |
1/1/2022 | 3,912 | 152 | 413 | 944 | N/A |
9/30/2021 | 3,637 | 341 | 445 | 788 | N/A |
6/30/2021 | 3,599 | 353 | 702 | 1,023 | N/A |
3/31/2021 | 3,596 | 411 | 333 | 618 | N/A |
12/31/2020 | 3,419 | 418 | 310 | 573 | N/A |
9/30/2020 | 3,395 | 214 | 339 | 645 | N/A |
6/30/2020 | 3,312 | 196 | 149 | 443 | N/A |
3/31/2020 | 3,172 | 164 | 508 | 760 | N/A |
12/31/2019 | 2,993 | 155 | 446 | 696 | N/A |
9/30/2019 | 2,877 | 366 | 335 | 500 | N/A |
6/30/2019 | 2,709 | 347 | 458 | 577 | N/A |
3/31/2019 | 2,467 | 302 | 305 | 457 | N/A |
12/31/2018 | 2,333 | 280 | 372 | 493 | N/A |
9/30/2018 | 2,098 | 228 | 458 | 600 | N/A |
6/30/2018 | 1,842 | 212 | N/A | 444 | N/A |
3/31/2018 | 1,679 | 185 | N/A | 339 | N/A |
12/31/2017 | 1,596 | 173 | N/A | 209 | N/A |
9/30/2017 | 1,511 | 172 | N/A | 79 | N/A |
6/30/2017 | 1,377 | 149 | N/A | 106 | N/A |
3/31/2017 | 1,245 | 145 | N/A | 106 | N/A |
12/31/2016 | 1,158 | 131 | N/A | 196 | N/A |
9/30/2016 | 1,014 | 119 | N/A | 210 | N/A |
6/30/2016 | 903 | 95 | N/A | 109 | N/A |
3/31/2016 | 852 | 83 | N/A | 103 | N/A |
12/31/2015 | 795 | 90 | N/A | 67 | N/A |
9/30/2015 | 725 | 94 | N/A | 36 | N/A |
6/30/2015 | 724 | 99 | N/A | 40 | N/A |
3/31/2015 | 727 | 103 | N/A | -16 | N/A |
12/31/2014 | 751 | 104 | N/A | 52 | N/A |
9/30/2014 | 786 | 99 | N/A | 2 | N/A |
6/30/2014 | 783 | 96 | N/A | -10 | N/A |
3/31/2014 | 782 | 91 | N/A | 66 | N/A |
12/31/2013 | 775 | 101 | N/A | -21 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: 002675's forecast earnings growth (45.9% per year) is above the savings rate (2.9%).
Winst versus markt: 002675's earnings (45.9% per year) are forecast to grow faster than the CN market (25.8% per year).
Hoge groeiwinsten: 002675's earnings are expected to grow significantly over the next 3 years.
Omzet versus markt: 002675's revenue (13.1% per year) is forecast to grow slower than the CN market (14% per year).
Hoge groei-inkomsten: 002675's revenue (13.1% per year) is forecast to grow slower than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: 002675's Return on Equity is forecast to be low in 3 years time (7.6%).